Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I investigator initiated inhalation safety trial of AB569 in healthy volunteers.

Trial Profile

A phase I investigator initiated inhalation safety trial of AB569 in healthy volunteers.

Suspended
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Nitrite (Primary)
  • Indications Burkholderia cepacia infections; Pseudomonal infections; Staphylococcal infections
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 19 Jun 2018 According to an Arch Biopartners media release, the company will seek regulatory guidance from the US FDA in the a pre-Investigational New Drug (pre-IND) meeting for AB-569. This trial will be on hold and will resume again after the IND application is opened and the FDA approves the phase I study.
    • 19 Jun 2018 Arch Biopartners media release, status changed from recruiting to suspended.
    • 27 Mar 2018 According to an Arch Biopartners media release, the first patients were recruited and enrolled in the trial in February 2018. Dr. Ralph Panos is the lead investigator of the trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top